Last reviewed · How we verify
Nicoderm patch first, then Aveva patch
A sequential nicotine replacement therapy regimen using transdermal patches to deliver nicotine and support smoking cessation.
A sequential nicotine replacement therapy regimen using transdermal patches to deliver nicotine and support smoking cessation. Used for Smoking cessation.
At a glance
| Generic name | Nicoderm patch first, then Aveva patch |
|---|---|
| Also known as | Brand name nicotine patch first, then generic nicotine patch |
| Sponsor | University of Maryland, Baltimore |
| Drug class | Nicotine replacement therapy |
| Target | Nicotinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Addiction Medicine / Smoking Cessation |
| Phase | FDA-approved |
Mechanism of action
Nicoderm patch provides initial nicotine replacement to reduce withdrawal symptoms and cravings during smoking cessation. The Aveva patch (if a follow-up formulation) would continue nicotine delivery at a potentially reduced dose as part of a tapering strategy. This combination approach aims to gradually wean patients off nicotine while maintaining compliance and minimizing relapse.
Approved indications
- Smoking cessation
Common side effects
- Skin irritation at patch site
- Headache
- Nausea
- Dizziness
- Sleep disturbances
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: